The SMi Group is proud to announce the return of the **12th annual ADMET** conference taking place in **London** on the **12th – 13th June 2017.**

Join our expert speaker panel at the 12th annual ADMET conference for yet another successful run! Presenting new developments, case studies and challenges in the areas of **DMPK. PBPK, PKPD, in vivo/ in vitro/ in silico, transporters, hazards** and s**afety assessment, ADMET modelling** and many more!

This event will explore ADMET technologies which determine properties of a drug candidate in the preclinical stage of drug discovery, structure based prediction of ADME properties, PK/PD modelling to validate drug targets and toxicity and many more.

ADMET 2017 will provide a series of practical case studies delivered by leading industry experts that will provide executives with useful tools and best practices to:

- Predict drug design interaction
- Evaluate drug design interaction
- Use a population pharmacokinetic approach to assess DDI
- Review the structure based prediction of ADME properties
- Learn about In-Vivo drug-drug interaction
- Optimise human ADMET studies to assess clinically-relevant drug bioavailability
- Gain insight into PK/PD modelling to validate drug targets and toxicity

FEATURED SPEAKERS:

- Ajit Narang, Senior Scientist, Genentech
- Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
- Ben-Fillippo Krippendorff, Franchise Leader PK/PD Immunology & Inflammation, Roche
- Carl Petersson, Associate Director Drug Disposition, Merck KGaA
- Eric Blomme, Vice President Preclinical Safety, AbbVie
- Handan He, Director, Section Head, Nonclinical PK/PD, Novartis
- Jackie Bloomer, Director, IVIVT, PTS, GSK
- Kiyoyuki Omoto, Scientist, Associate Research Fellow, Pfizer
- Kunal Taskar, Senior Investigator & Associate Fellow, GSK
- Laurent Salphati, Principal Scientist, Genentech
- Matthias Wittwer, Laboratory Head DMPK-BANP-NCPK, Bayer
- Na Li, Senior Staff Scientist, Corning
- Peter Littlewood, Senior Director Head of DMPK Europe, Vertex Pharmaceuticals

- Rob Young, Senior Scientific Investigator & GSK Associate Fellow, GSK
- Sheila Annie Peters, Head, Translational Quantitative Pharmacology, Merck KGaA
- Timothy Schulz-Utermoehl, Director of DMPK, Sygnature Discovery
- Valeriu Damian, Director System Modeling & Translational Biology, GSK
- Elisabetta Chiarparin, Head of Oncology Analytical and Structural Chemistry, AstraZeneca
- Robert van Waterschoot, Head of Pharmacokinetics, Dynamics & Metabolism (PDM) Leaders, Roche

FEATURED SPEAKERS:

Genentech, Bayer, Roche, Merck KGaA, AstraZeneca, AbbVie, Novartis, Pfizer, GSK, Corning, Vertex Pharmaceuticals,

CONFERENCE HIGHLIGHTS:

- Learn about new technologies for ADMET testing, including computer based testing
- ADME/PK Optimisation for Drug Design and Discovery
- Preclinical In Vivo Pharmacology Testing and Translational PK/PD
- Developments in Drug Screening Technology
- In Vitro to Human In Vivo Translation
- Physiologically Based PK Modeling
- Predictive Human Toxicity, Transporters and ADMET Studies from Vertex, Merck KGaA, GSK
- Listen to presentations explaining methods to predicting Drug-Drug Interactions with in vivo and in vitro data knowledge

EARLY BIRDS:

Book by 28th February - save £300

Book by 3th1 March - save £200

Book by 28th April - save £200

KEY WORDS:

ADMET, in vivo, in vitro, in silico, Pharmacology, DDI, Genotoxic, Assay, DMPK, Metabolites

SMi presents its 12th conference on
ADMET 2017
12 - 13 JUNE | LONDON, UK | www.admet-event.com